Zentalis Pharmaceuticals (ZNTL) Price & Analysis

Compare

340 Followers

ZNTL Stock Chart & Stats

$1.41

-$0.17(-5.69%)

At close: Jan 08 4:00 PM EST

$1.41

-$0.17(-5.69%)

Day’s Range― - ―

52-Week Range$1.01 - $3.33

Previous CloseN/A

Volume750.15K

Average Volume (3M)716.92K

Market Cap

$101.15M

Enterprise Value-$178.60M

Total Cash (Recent Filing)$280.70M

Total Debt (Recent Filing)$36.71M

Price to Earnings (P/E)―

Beta2.05

Next Earnings

Mar 04, 2026

EPS Estimate

-0.43

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.37

Shares Outstanding72,250,780

10 Day Avg. Volume819,524

30 Day Avg. Volume716,917

Financial Highlights & Ratios

PEG Ratio0.03

Price to Book (P/B)0.64

Price to Sales (P/S)3.19

P/FCF Ratio-1.26

Enterprise Value/Market Cap-1.77

Enterprise Value/Revenue-6.65

Enterprise Value/Gross Profit-6.71

Enterprise Value/Ebitda1.23

Forecast

1Y Price Target

$6.60

Price Target Upside368.09% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering6

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical TrialsEnrollment remains ongoing in Part 2a of the ongoing DENALI clinical trial in platinum resistant ovarian cancer, with potential for accelerated approval based on data.

Financial HealthEnded the third quarter with approximately $280.7 million in cash and equivalents expected to support ongoing trials.

Regulatory ApprovalThe company expects to report registration-intent topline results for both segments by the end of the year, believing these data could support an accelerated approval, subject to FDA review.

Bears Say

Zentalis Pharmaceuticals News

Zentalis Pharmaceuticals Announces Stock Repurchase Agreement

Zentalis Pharmaceuticals ( ($ZNTL) ) has issued an update. Zentalis Pharmaceuticals announced on December 15, 2025, that it...

39m ago

ZNTL

Zentalis Pharmaceuticals Reports Q3 2025 Financial Results

Zentalis Pharmaceuticals Inc ( ($ZNTL) ) has released its Q3 earnings. Here is a breakdown of the information...

1M ago

ZNTL

Zentalis price target lowered to $4 from $8 at Morgan Stanley

Morgan Stanley analyst Michael Ulz lowered the firm’s price target on Zentalis (ZNTL) to $4 from $8 and...

1M ago

ZNTL

Buy Rating for Zentalis Pharmaceuticals Driven by Promising Clinical Progress and Strategic Focus on PROC

TD Cowen analyst Tyler Van Buren has maintained their bullish stance on ZNTL stock, giving a Buy rating...

1M ago

ZNTL

Zentalis Pharmaceuticals Reports Q3 2025 Financial Results

Zentalis Pharmaceuticals ( ($ZNTL) ) has shared an announcement. Zentalis Pharmaceuticals reported its third quarter 2025 financial results,...

1M ago

ZNTL

Zentalis reports Q3 EPS (37c), consensus (48c)

“We are pleased with our continued disciplined execution of the DENALI clinical trial this quarter, supporting late-stage development...

1M ago

ZNTL

Strategic Advancements and Promising Developments Drive Buy Rating for Zentalis Pharmaceuticals

In a report released today, Andres Y. Maldonado from H.C. Wainwright reiterated a Buy rating on Zentalis Pharmaceuticals,...

2M ago

ZNTL

Zentalis board member Letai frontrunner to lead NCI, STAT reports

Anthony Letai, a cancer researcher and oncologist at the Dana-Farber Cancer Institute and Harvard University and a member...

3M ago

ZNTL

Zentalis Pharmaceuticals Announces New Chief Legal Officer

An update from Zentalis Pharmaceuticals ( ($ZNTL) ) is now available. On August 26, 2025, Zentalis Pharmaceuticals announced...

4M ago

ZNTL

Zentalis CLO Andrea Paul to depart, James Bucher to succeed

Zentalis (ZNTL) announced the appointment of James Bucher as chief legal officer and corporate secretary, effective September 18....

4M ago

ZNTL

Zentalis price target lowered to $5 from $6 at Wells Fargo

Wells Fargo lowered the firm’s price target on Zentalis (ZNTL) to $5 from $6 and keeps an Equal...

4M ago

ZNTL

Strategic Advancements and Promising Clinical Data Support Buy Rating for Zentalis Pharmaceuticals

In a report released today, Andres Y. Maldonado from H.C. Wainwright reiterated a Buy rating on Zentalis Pharmaceuticals,...

4M ago

ZNTL

Zentalis Pharmaceuticals: Hold Rating Amid Delayed Catalysts and Market Skepticism

Analyst Derek Archila from Wells Fargo maintained a Hold rating on Zentalis Pharmaceuticals and decreased the price target...

4M ago

ZNTL

Zentalis Pharmaceuticals Reports Improved Financial Results

Zentalis Pharmaceuticals Inc ( ($ZNTL) ) has released its Q2 earnings. Here is a breakdown of the information...

4M ago

ZNTL

ZNTL FAQ

What was Zentalis Pharmaceuticals’s price range in the past 12 months?

Zentalis Pharmaceuticals lowest stock price was $1.01 and its highest was $3.33 in the past 12 months.

What is Zentalis Pharmaceuticals’s market cap?

Zentalis Pharmaceuticals’s market cap is $101.15M.

When is Zentalis Pharmaceuticals’s upcoming earnings report date?

Zentalis Pharmaceuticals’s upcoming earnings report date is Mar 04, 2026 which is in 79 days.

How were Zentalis Pharmaceuticals’s earnings last quarter?

Zentalis Pharmaceuticals released its earnings results on Nov 10, 2025. The company reported -$0.37 earnings per share for the quarter, beating the consensus estimate of -$0.528 by $0.158.

Is Zentalis Pharmaceuticals overvalued?

According to Wall Street analysts Zentalis Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Zentalis Pharmaceuticals pay dividends?

Zentalis Pharmaceuticals does not currently pay dividends.

What is Zentalis Pharmaceuticals’s EPS estimate?

Zentalis Pharmaceuticals’s EPS estimate is -0.43.

How many shares outstanding does Zentalis Pharmaceuticals have?

Zentalis Pharmaceuticals has 72,250,780 shares outstanding.

What happened to Zentalis Pharmaceuticals’s price movement after its last earnings report?

Zentalis Pharmaceuticals reported an EPS of -$0.37 in its last earnings report, beating expectations of -$0.528. Following the earnings report the stock price went up 6.061%.

Which hedge fund is a major shareholder of Zentalis Pharmaceuticals?

Currently, no hedge funds are holding shares in ZNTL

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Zentalis Pharmaceuticals Stock Smart Score

Underperform

Fundamentals

Return on Equity

-49.18%

Trailing 12-Months

Asset Growth

-28.47%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Zentalis Pharmaceuticals

Zentalis Pharmaceuticals (ZNTL) is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The company operates in the biotechnology sector, leveraging its expertise in medicinal chemistry and translational science to develop drug candidates aimed at improving patient outcomes in oncology. Zentalis' core products include a pipeline of proprietary agents designed to address unmet medical needs in cancer treatment.

Zentalis Pharmaceuticals (ZNTL) Earnings & Revenues

Historic Earnings Reports

ZNTL Stock 12 Month Forecast

Average Price Target

$6.60

▲(368.09% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","11":"$11","2.75":"$2.75","5.5":"$5.5","8.25":"$8.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$6.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2.75,5.5,8.25,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Apr<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.5,2.1538461538461537,2.8076923076923075,3.4615384615384617,4.115384615384615,4.769230769230769,5.423076923076923,6.076923076923077,6.730769230769231,7.384615384615385,8.038461538461538,8.692307692307693,9.346153846153847,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.5,1.8923076923076922,2.2846153846153845,2.676923076923077,3.069230769230769,3.4615384615384617,3.853846153846154,4.246153846153846,4.638461538461538,5.030769230769231,5.423076923076923,5.815384615384615,6.207692307692308,{"y":6.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.5,1.6923076923076923,1.8846153846153846,2.076923076923077,2.269230769230769,2.4615384615384617,2.653846153846154,2.8461538461538463,3.0384615384615383,3.230769230769231,3.4230769230769234,3.6153846153846154,3.807692307692308,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.8,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.47,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.32,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.66,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.03,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.07,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.39,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.45,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.28,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.34,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.72,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.54,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.5,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >